Equities

Hangzhou TianMuShan Pharmaceutical Enterprise Co Ltd

600671:SHH

Hangzhou TianMuShan Pharmaceutical Enterprise Co Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (CNY)6.41
  • Today's Change-2.70 / -29.64%
  • Shares traded1.30m
  • 1 Year change-45.21%
  • Beta0.3121
Data delayed at least 15 minutes, as of Sep 13 2024 08:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Hangzhou TianMuShan Pharmaceutical Enterprise Co., Ltd is a China based company principally engaged in the research and development, production and sales of pharmaceuticals and related health products. The Company is mainly engaged in the manufacture of chemical drug substances, processing of Chinese herbal pieces as well as the manufacture of traditional Chinese medicine preparation and Western medicine. The Company's main products are bright eye drops, FufangXianzhuliYe, amoxicillin and clavulanate potassium tablets, Hechedazao Jiaonang, Liu Wei Di Huang oral liquid, menthol, and peppermint oil. The Company mainly operates its business in the domestic market.

  • Revenue in CNY (TTM)160.35m
  • Net income in CNY-14.51m
  • Incorporated1993
  • Employees380.00
  • Location
    Hangzhou TianMuShan Pharmaceutical Enterprise Co LtdRoom 1803-1804, Boya Times Center, ShixiHANGZHOU 311200ChinaCHN
  • Phone+86 57 163722229
  • Fax+86 57 163715400
  • Websitehttp://www.hztmyy.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Jbm (Healthcare) Ltd603.63m121.45m1.07bn279.009.461.206.261.770.14790.14790.73381.170.46454.255.982,324,068.009.834.3812.045.5252.1446.4721.1612.691.2589.680.115532.9824.6216.09128.5119.992.26--
Lincoln Pharmaceuticals Ltd513.13m83.00m1.07bn1.70k12.921.9511.502.0948.2548.25298.31319.160.8283.773.403,514,339.0013.3913.9515.8516.5452.6050.6516.1814.713.6460.480.00213.4413.769.6627.9913.8821.543.71
Kotra Industries Berhad367.13m72.27m1.08bn744.0014.962.4211.342.950.30070.30071.531.860.677--6.41304,508.1013.3315.8216.2219.09--74.5519.6822.411.721,528.510.003853.71-6.465.60-31.6414.9831.5028.07
Bliss GVS Pharma Ltd687.26m54.47m1.09bn831.0020.301.2612.761.595.945.9475.5596.050.64543.101.989,628,987.005.806.467.048.2250.2643.918.999.923.74--0.08257.922.48-3.036.49-9.42-8.33-12.94
Elutia Inc181.06m-507.91m1.10bn54.00------6.06-3.05-2.861.12-2.280.53032.325.08462,722.20-148.77-42.93-1,212.93-79.3442.4643.32-280.53-64.160.6842-0.6561-----49.69-8.71-25.39--12.74--
Hyloris Pharmaceuticals SA38.81m-93.45m1.11bn24.00--4.18--28.55-0.4281-0.42810.17891.240.0989--1.19---23.82-22.79-28.07-28.0996.9592.05-240.77-815.53----0.0516--131.8987.11-29.18--89.12--
Hangzhou Tianmushan Phrmtcl ntrprs C Ltd160.35m-14.51m1.11bn380.00--33.17--6.92-0.1192-0.11921.320.27460.45372.293.43421,978.40-4.39-6.93-22.04-18.9236.6933.95-9.69-16.420.4497-1.950.6938--11.82-19.4243.35---24.89--
AFT Pharmaceuticals Ltd831.95m66.45m1.13bn110.0017.063.0315.121.360.14890.14891.860.83721.252.344.301,776,464.009.9611.4413.7216.4945.1745.657.999.501.236.690.26834.4324.7518.0846.51--22.42--
Data as of Sep 13 2024. Currency figures normalised to Hangzhou TianMuShan Pharmaceutical Enterprise Co Ltd's reporting currency: Chinese Yuan Renminbi CNY
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.